2017 a record year for LEO Pharma with sales hitting over 10 billion kroner

2 March 2018

In 2017, LEO Pharma helped more than 80 million patients, increased revenues by 8% in local currencies, and generated revenues at more than 10 billion Danish kroner ($1.65 billion) for the first time in the company’s 110 year old history.

Earnings before interest and tax (EBIT) more than doubled to 852 million kroner despite significant investments in new products, on sales of 10.48 billion kroner.

The foundation-owned company’s operating profit before depreciation and amortization was above expectations going up 49% from 1,346 million kroner in 2016 to 2,005 million kroner in 2017.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK